ArticleDiabetes research and clinical practice2020
Is DPP4 inhibition a comrade or adversary in COVID-19 infection.
Article in Diabetes research and clinical practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Effect of Antidiabetic Therapy on Clinical Outcomes of COVID-19 Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis.The Annals of pharmacotherapy · 2023 · on this mapPooled it
- Dipeptidyl peptidase-4 inhibitors and the risk of infection: A systematic review and meta-analysis of cardiovascular outcome trials.World journal of diabetes · 2024Article
- Efficacy and Safety of Sitagliptin in the Treatment of COVID-19.Journal of pharmacy practice · 2023Review
- DPP-4 Inhibitors as a savior for COVID-19 patients with diabetes.Future virology · 2023Review
- Integrating heterogeneous data to facilitate COVID-19 drug repurposing.Drug discovery today · 2022Review
- Host-Cell Surface Binding Targets in SARS-CoV-2 for Drug Design.Current pharmaceutical design · 2022Review
- Drug Repurposing to Identify Nilotinib as a Potential SARS-CoV-2 Main Protease Inhibitor: Insights from a Computational andJournal of chemical information and modeling · 2021Article
- Molecular Mechanisms of Possible Action of Phenolic Compounds in COVID-19 Protection and Prevention.International journal of molecular sciences · 2021Review
- Dipeptidyl peptidase 4 inhibitors: Applications in innate immunity?Biochemical pharmacology · 2021Review
- Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Article
- DPP-4 inhibition and COVID-19: From initial concerns to recent expectations.Diabetes & metabolism · 2021Review
- Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19.Molecular and cellular biochemistry · 2021Review
- Landscape Profiling Analysis of DPP4 in Malignancies: Therapeutic Implication for Tumor Patients With Coronavirus Disease 2019.Frontiers in oncology · 2021Article
- Sodium-glucose co-transporter-2 inhibitors and susceptibility to COVID-19: A population-based retrospective cohort study.Diabetes, obesity & metabolism · 2021Article
- Long-term inhibition of dipeptidyl-peptidase 4 reduces islet infiltration and downregulates IL-1β and IL-12 in NOD mice.International immunopharmacology · 2020Article
- Article
- Can phytotherapy with polyphenols serve as a powerful approach for the prevention and therapy tool of novel coronavirus disease 2019 (COVID-19)?American journal of physiology. Endocrinology and metabolism · 2020Review
- Repurposing existing drugs for COVID-19: an endocrinology perspective.BMC endocrine disorders · 2020Article
- DPP-4 Inhibitors in the Prevention/Treatment of Pulmonary Fibrosis, Heart and Kidney Injury Caused by COVID-19-A Therapeutic Approach of Choice in Type 2 Diabetic Patients?Frontiers in pharmacology · 2020Article
- COVID-19: molecular targets, drug repurposing and new avenues for drug discovery.Memorias do Instituto Oswaldo Cruz · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension and Diabetes are the most common comorbid conditions in patients with COVID-19 and has been shown to adversely impact prognosis globally. It has been shown that hyperglycemia is one of the factors that increases the risk of poor outcomes in these patients. These patients are usually on multiple medications and recently a series of discussion on how Dipeptidyl peptidase 4 inhibitors (DPP4i) may be beneficial in these patients has been presented. This commentary presents a nuanced debateon why the DPP4i may not bebeneficial in COVID-19 and that caution needs to be addressed in making any judgementsuntil real world data is available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.